Peer-reviewed article
ATRT-09. IDENTIFICATION OF POTENTIAL GENETIC DRIVERS OF METHOTREXATE (MTX) RESISTANCE IN ATYPICAL TERATOID RHABDOID TUMOURS (ATRT) THROUGH A GENOME-WIDE RNAI SCREEN
Kannappan S, Gupa M, Kang S, Tran A, Thakur S et al. ·
Summary
Written by AI, not yet AICS's view · claude-haiku-4-5-20251001This is a laboratory study identifying genetic markers associated with resistance to methotrexate chemotherapy in atypical teratoid rhabdoid tumours (ATRT), a rare childhood brain cancer. Researchers used a genome-wide screen of cancer cell lines to identify three genes (TGIF1, HIF3A, and PGAM2) whose depletion made cells resistant to the drug. While the work relates to childhood cancer treatment, it is basic molecular research conducted in cell culture rather than research on child well-being outcomes.
Key points
- Three genes (TGIF1, HIF3A, PGAM2) were identified as potential markers of methotrexate resistance in ATRT cell lines
- Cells with depleted TGIF1, HIF3A, or PGAM2 showed significantly higher IC50 values (resistance) compared to control cells
- Over 60% of cells with depleted target genes survived maximum methotrexate treatment versus less than 20% of control cells
- The study used an unbiased genome-wide RNAi screen covering 8,000 genes with 24,000 distinct shRNAs
Limitations
This is in vitro cell culture research with no clinical data on children, no evaluation of treatment outcomes in patients, and no assessment of child well-being or health impacts. The findings are preliminary molecular markers that may not translate to clinical benefit.
Abstract
Abstract ATRT of the CNS constitute a group of rare and aggressive early childhood tumors with poor prognosis. While there are differing chemotherapeutic regimens for ATRT, high-dose MTX is a crucial component of many therapeutic protocols. Currently, the biological mechanisms contributing to the generation of MTX resistance in ATRT are unknown. To identify genes involved in MTX resistance in ATRT, an unbiased genome-wide RNAi screen on ATRT cell lines was conducted using 24,000 distinct shRNAs covering 8,000 genes. ATRT cells were transfected with a retrovirus containing pRS-shRNA vectors and treated with puromycin for selection. The resulting cells were treated with MTX to identify resistant clones and resistant colonies were then isolated and amplified individually. Presence of shRNA inserts in each colony was determined by PCR using pRS forward and reverse primers. PCR products within each of the three resistant colonies were sequenced, leading to the identification of three distinct genes, TGIF1, HIF3A and PGAM2, as potential indicators of resistance. Western blotting verified depletion of these proteins in their respective colonies. Proliferation assays were then conducted on cells from each resistant colony alongside control cells to confirm that the identified drivers conferred resistance. Sensitivity to MTX was significantly lower in TGIF1-depleted (IC50=212±8.48nM, n=3), HIF3A-depleted (IC50=52±4.68nM, n=3) and PGAM2-depleted (IC50=41±4.13nM, n=3) cells compared to control cells (IC50=19±2.87nM, n=3), (p<0.001). In addition, more than 60% of TGIF1, HIF3A, and PGAM2-depleted cells survived the maximum MTX treatment (100nM), while less than 20% of control cells survived this treatment. Our study using an unbiased genome-wide RNAi screen approach has shown that depletion of TGIF1, HIF3A and PGAM2 are potential molecular markers of MTX resistance in ATRT. Screening for their occurrence may help to identify patients at high risk of MTX resistance and may also serve as targets for future novel therapeutics development.